Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00474864
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2007-05-15
Brief Title:
Study To Evaluate The Effects Of GW856553 On Endothelial FunctionVascular Compliance In Subjects With Dyslipidaemia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Parallel Study To Evaluate The Effects Of GW856553 On Endothelial FunctionVascular Compliance In Subjects With Dyslipidaemia
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The rationale for this study is to determine whether GW856553 75mg BD for 28 days has an effect on endothelial function in dyslipidaemic subjects as assessed by venous occlusion plethysmography using brachial artery acetylcholine infusion This will establish consistency with preclinical findings as well as confirm a physiologic human response at the current safe maximal dose Safety specifically serum liver function testing and tolerability will also be evaluated in this trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None